EU Message: This test is not available to persons established in the EU.
Explore How Genetics Influence Neurodiversity
DNA Signature – Spectrum Map is a specialized genomic tool engineered to evaluate the interconnected biochemical pathways influencing neurodivergent traits, including Autism Spectrum conditions, ADHD, executive function variations, and sensory processing differences.
By mapping genomic interactions across neuro-chemical balance, detoxification capacity, immune/histamine regulation, and nutrient metabolism, it provides practitioners with an objective blueprint of each patient’s unique physiological landscape. This panel helps clarify the underlying drivers behind common overlapping challenges, such as sleep disruptions, environmental sensitivities, GI issues, and altered nutrient processing, empowering clinicians to design highly targeted, personalized intervention strategies.
Designed as a genetic companion to MosaicDX Organic Acids Test (OAT) and EnviroTOX® Profiles
Multi-System Reactivity & High Environmental Sensitivity
Patients with Sleep Architecture Disruptions
Methylation & Neuro-Nutritional Bottlenecks
Details
Why Use the DNA Signature – Spectrum Map Profile?
DNA Signature – Spectrum Map is a specialized genomic tool designed to evaluate the interconnected biochemical pathways that influence neurodivergent traits, including Autism Spectrum conditions, ADHD, executive function variations, and sensory processing differences. By assessing how genomic variants across neuro-chemical, detoxification, immune, and metabolic pathways interact, this panel provides practitioners with an objective blueprint to better understand and support each patient’s unique physiological landscape.
Core Functional Domains Evaluated
Executive Function & Neuro-Chemical Balance
Attention & Cognitive Focus: Maps genetic variations associated with ADHD Propensity and Attention Regulation to help clarify underlying neuro-chemical dynamics.
Methylation & Neurotransmitter Support: Evaluates core Methylation Traits that drive central nervous system turnover, DNA repair, and the synthesis and breakdown of key neurotransmitters.
Biotransformation Pathways: Assesses Phase I and Phase II detoxification kinetics, including CYPs (Phase 1 detoxification), Glucuronidation, and overall detoxification capacity.
Pesticide & Chemical Clearance: Evaluates PON (Paraoxonase) activity, an enzyme vital for breaking down organophosphates, pesticides, and oxidized lipids.
Mast Cell & Histamine Dynamics: Maps genetic markers involved in histamine/mast cell activation, providing insight into neuro-inflammation, food/environmental sensitivities, and gut-brain reactivity.
Nutrient Metabolism & Essential Cofactors
B-Vitamin Utilization: Assesses functional conversion efficiency for foundational cofactors such as Vitamin B12, Vitamin B6, and Folate.
Essential Fatty Acid Processing: Maps Omega 3 metabolism and Omega 6 metabolism to help optimize cell membrane fluidity and neuro-protective fatty acid ratios.
Metabolic & Mineral Status: Pinpoints genetic susceptibility to Magnesium deficiency, Glucose metabolism, and lipid-related markers.
Sleep Architecture & Circadian Sensitivity
Restorative Sleep & Resilience: Evaluates genetic drivers of Reported Sleep Quality and biological Sleep Deprivation Susceptibility.
Our high-complexity laboratory is committed to delivering accurate and reliable results in coordination with these top licensure programs:
Analytes
From a single easy-to-collect buccal swab you will receive a personalized polygenic risk score for the following traits:
ADHD Propensity
Attention Regulation
Methylation Trait
Glucuronidation
Detoxification Capacity
CYPs
PON
Histamine / Mast Cell Activation
Omega 3 Metabolism
Omega 6 Metabolism
Glucose Metabolism
Magnesium Deficiency Risk
Vitamin B12 / B6 / Folate Nutrient Traits
CHD from Lower LDL
Reported Sleep Quality
Caffeine Effect on Sleep
Sleep Deprivation Susceptibility
Sample Reports
The DNA Methylation Profile report aids clinical support for patients by pinpointing SNPs that could potentially impact health and disease risk.
MosaicDX offers patient-friendly sample collection kits that simplify testing. Our kits include visual, step-by-step instructions for test preparation and sample collection, personalized shipping cards, and pediatric collection bags if needed. With MosaicDX, patients can easily collect samples for testing with confidence and accuracy.
No, we do not. A genetic carrier refers to an individual who has inherited a recessive allele that has been shown to be responsible for an autosomal recessive disease or trait. A genetic carrier only has one recessive allele so while they do not show signs or symptoms of the trait or disease, they are able to pass along the recessive gene to their child. Our genetic testing is for screening purposes only to assess risk or predisposition for certain traits associated with health and wellness.
No. We do not use patient samples for further research or testing. We may use your de-identified and anonymized data to help improve our algorithm and reports. Your data will not be sold or shared to or with any 3rd parties/commercial interests.
Yes, we can delete the patient’s raw genetic sequence at any time. Please note that applicable federal and state laws require us to retain your patient report and the subset of your data that was used to generate that report for a specified period of time. We will be happy to delete any and all of your data that we are legally allowed to delete upon request. Please submit your request here.
We implement rigorous selection criteria when choosing which genes or SNPs to include in our panels. The selection and validation criteria are based upon peer-reviewed studies that show a significant association between the SNP variant and trait or condition, the magnitude of the odds ratio (OR) or hazard ratio (HR) to assess risk related to the variant, as well as the population or populations the gene and SNP variant were studied in, the population size, and replication of findings.
A genotype refers to the actual inherited genetic material of an individual that can influence or determine certain characteristics or traits. A phenotype is how the genotype is actually expressed, that is the observable or measurable characteristics or traits of an individual.
SNP is also called a Single Nucleotide Polymorphism. Your DNA consists of 4 main building blocks (nucleotides), Adenine (A), Thymine (T), Guanine (G), and Cytosine (C). In certain locations within your DNA, one person may have an A, whereas another may have a G. This difference in the base pair is often called a variant. This variant is an SNP.
In most situations, you do not have to resubmit a DNA buccal swab sample if you later want to order additional panels. The only time a new DNA buccal swab would need to be resubmitted is if the assay has had significant changes, or the patient previously requested that their DNA sequencing results be deleted.
Patients are sent a DNA Signature Collection Kit containing instructions, 1 cheek swab, a DNA Sample Envelope and a prepaid return envelope and biohazard zip-lock bag. Instructions can also be found on our website on the DNA Signature Profiles web page, along with an easy-to-follow video.
A person’s polygenic risk score is a statistical calculation based on the presence or absence of multiple genomic variants without taking environmental or other factors into account
Different states have regulations that define the scope of practice for practitioners. It is the practitioner’s responsibility to abide by these rules. Check with your state board of health to determine any restrictions related to laboratory testing. Please note, Mosaic Diagnostics does not offer testing in New York.
Once you have opened your account, you have the options of ordering kits to stock in your office or drop-ship kits directly to your patients through your MosaicDX portal.
Watch our short tutorial videos on how to conveniently
Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009;126(1):51-90. PMID 19506906.
Noble EP, et al. D2 dopamine receptor gene and obesity. Int J Eat Disord. 1994;15(3):205-17. PMID 9354503.
Lachman HM, et al. Human catechol-O-methyltransferase pharmacogenetics. Pharmacogenetics. 1996;6(3):243-50. PMID 8807664; updated ref PMID 17033636.
Tost H, et al. A common allele in the oxytocin receptor gene (OXTR) impacts prosocial temperament and human hypothalamic-limbic structure and function. Proc Natl Acad Sci. 2010.
Moyer RA, et al. Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology. 2011;36(4):753-62. PMID
Hawi Z, et al. Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. Mol Psychiatry. 2002;7(7):718-25. PMID 11056459.
Barr CL, et al. Linkage study of two regions of chromosome 20p in attention deficit hyperactivity disorder. Am J Med Genet B. 2004;127B(1):10-4. [SNAP-25 3′-UTR DraI, PMID 16924267]
Manor I, et al. The correlation between motivational and neurocognitive functioning in adults with ADHD and the role of dopaminergic sensitization. Psychopharmacology. 2002;160(1):50-9.
Nováková M, et al. CLOCK and ARNTL (BMAL1) as candidate genes for human attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2012. PMID 19942480.
Katzenberg D, et al. A CLOCK polymorphism associated with human diurnal preference. Sleep. 1998;21(6):569-76. PMID 17637780.
Brookes KJ, et al. A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch Gen Psychiatry. 2006;63(1):74-81. PMID 17143299.
Stevenson J, et al. Attention deficit hyperactivity disorder (ADHD) and the role of histamine: a new approach. J Child Psychol Psychiatry. 2010. PMID 14636362.
Dіaz-García C, et al. MTHFR gene polymorphisms and autism spectrum disorders: systematic review and meta-analysis. J Autism Dev Disord. 2025. PMID 39727424.
Wan L, et al. Association between MTHFR C677T polymorphism and autism spectrum disorders: a meta-analysis. Genes (Basel). 2023. PMID 36835449.
Pu D, et al. Association between MTHFR gene polymorphisms and the risk of autism spectrum disorders: a meta-analysis. Autism Res. 2013. PMID 29809000.]
Leclerc D, et al. Molecular cloning and characterization of human methionine synthase reductase. J Biol Chem. 1998;273(14):8051-8. PMID 9916843.
Frustaci A, et al. Oxidative stress-related biomarkers in autism: systematic review and meta-analyses. Free Radic Biol Med. 2012;52(10):2128-41. PMID 22206512.
Nazki FH, et al. Folate: metabolism, genes, polymorphisms and the associated diseases. Gene. 2014;533(1):11-20. PMID 28034905.
James SJ, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B. 2006;141B(8):947-56. PMID 16762935.
James SJ, et al. Abnormal transmethylation/transsulfuration metabolism and DNA hypomethylation among parents of children with autism. J Autism Dev Disord. 2008. PMID
Li YJ, et al. MTRR A66G polymorphism and autism spectrum disorder risk: a meta-analysis. PLoS One. 2012. PMID 22851460. [MTRR A66G meta-analysis autism]
Mohammad NS, et al. Aberrant methionine-homocysteine cycle in the pathophysiology of Alzheimer’s disease. Front Neurosci. 2013. PMID 23759472.
Ananth CV, et al. Placental abruption, maternal smoking and BHMT gene polymorphism. Placenta. 2011. PMID 21170374.
Waterland RA, et al. Post-weaning diet affects genomic imprinting at the insulin-like growth factor 2 locus. Hum Mol Genet. 2006. PMID 18796436.
Parle-McDermott A, et al. The 776CG variant of human MTHFD1 is associated with spina bifida. J Hum Genet. 2006;51(6):535-8. PMID 15994883.
Brody LC, et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase is a maternal genetic risk factor for neural tube defects. Am J Hum Genet. 2002;71(5):1207-15. PMID
Parle-McDermott A, et al. MTHFD1 R653Q polymorphism is a maternal risk factor for severe abruptio placentarum. Placenta. 2005. PMID 20479883.
Türkmen S, et al. Paraoxonase 1 (PON1) gene polymorphism in children with autism spectrum disorders. Genet Test Mol Biomarkers. 2012;16(9):1021-6. PMID 22213127.
Saad K, et al. Oxidative stress and mitochondrial dysfunction in autism spectrum disorder. J Clin Med. 2018. PMID 26634413.
D’Amelio M, et al. Paraoxonase gene variants are associated with autism in North America, but not in Italy: possible regional specificity in gene-environment interactions. Mol Psychiatry. 2005;10(11):1006-16. PMID 18706440.
Pasca SP, et al. One carbon metabolism disturbances and the C677T MTHFR gene polymorphism in children with autism spectrum disorders. J Cell Mol Med. 2009. PMID 28765446.
Iyer L, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). J Clin Invest. 1998;101(4):847-54. PMID 12432533.
Stingl JC, et al. Mechanism, prevention and clinical implications of nonalcoholic fatty liver disease-associated attenuation of CYP expression and activity. Expert Opin Drug Metab Toxicol. PMID 25417751.
Jakobsson J, et al. Large number of ingested calories does not affect the cardiovascular effects of coffee. Eur J Clin Nutr. 2004. PMID 14580788.
Higashi MK, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287(13):1690-8. PMID 18385512.
Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343-50. PMID
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-41. PMID 26990094.
Ingelman-Sundberg M, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496-526. PMID 20506139.
Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev. 1997;77(2):517-44. PMID 8976225.
Bae S, et al. Association of CYP2E1 polymorphism with NAPQI-induced hepatotoxicity. Drug Metab Pharmacokinet. 2010. PMID 18946086.
McCarver DG, et al. The EtOH-inducible CYP2E1 orthologs from mouse, rat, rabbit, dog, and human are highly conserved. Drug Metab Dispos. 1998. PMID 14737204.
Cosma GN, et al. Analysis of CYP1A1 polymorphisms in a population with increased occupational exposure to polycyclic aromatic hydrocarbons. Cancer Epidemiol. 2000. PMID
Cascorbi I, et al. Homozygous rapid aryl hydrocarbon hydroxylase activity is associated with lung cancer. Pharmacogenetics. 1996;6(5):395-401. PMID 9887150. [CYP1A1 Ile462Val]
Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24. PMID 19640226.
Bhatt DL, et al. Genotype-guided warfarin dosing versus standard dosing. N Engl J Med. 2023. PMID 38389782.
Strange RC, et al. Glutathione-S-transferase family of enzymes. Mutat Res. 2001.
Blanco G, et al. Polymorphism of CYP2C9 and CYP2C19: clinical pharmacological implications. Pharmacol Rep. 2012. PMID 22992668.
Bièche I, et al. Quantification of CYP1A1 and CYP1B1 gene expression in human breast carcinoma. Cancer Res. 2004. PMID 17671436.
Koch HM, et al. Internal exposure of the general population to DEHP and other phthalates: determination of secondary and primary phthalate monoester metabolites in urine. J Expo Sci Environ Epidemiol. 2003. PMID 21289003.
Cornelis MC, et al. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006;295(10):1135-41. PMID 16835424.
Palatini P, et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens. 2009;27(8):1594-601. PMID 18285789.
Sachse C, et al. Functional significance of a C→A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47(4):445-9. PMID 28119488.
Zhou SF, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. PMID 31696945.
Torgerson DG, et al. Meta-analysis and imputation refines the association of 15q25 with asthma and identifies IL-33 as the major candidate gene. Nat Genet. 2011;43(5):480-8. PMID 21926971.
Moffatt MF, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med. 2010;363(13):1211-21. PMID 20860503.
Weidinger S, et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. PLoS Genet. 2008;4(8):e1000166. PMID 22197950.
Granada M, et al. A combined strategy of discovery and replication identifies a candidate gene for total IgE levels in two European populations. Hum Mol Genet. 2012. PMID 23093923.
Schmitz J, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-90.
Van Eerdewegh P, et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature. 2002. PMID 15361864.
Heinzmann A, et al. Genetic variants of IL-13 signalling and human asthma and atopy. Hum Mol Genet. 2000;9(4):549-59. PMID 10535999.
Howard TD, et al. Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet. 2002;70(1):230-6. PMID 12415283.
Namkung JH, et al. IL-5 and IL-5 receptor alpha polymorphisms are associated with atopic dermatitis in Koreans. Allergy. 2007. PMID 20308738.
Schaeffer L, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet. 2006;15(11):1745-56. PMID 18931676.
Malerba G, et al. SNPs of the FADS gene cluster are associated with polyunsaturated fatty acids in a cohort of patients with cardiovascular disease. Lipids. 2008;43(4):289-99.
Steer CD, et al. FADS2 polymorphisms modify the effect of breastfeeding on child IQ. PLoS One. 2013. PMID 26352254.
Bent S, et al. Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism. J Am Acad Child Adolesc Psychiatry. 2014. PMID 25498469.
Sweeney MR, et al. Persistent circulating unmetabolised folic acid in a setting of liberal voluntary folic acid fortification. Implications for further mandatory fortification? BMC Public Health.
PMID 27003487.
Bailey RL, et al. Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in adults. Am J Clin Nutr. 2010. PMID 24367737.
Jemec GB, et al. Endothelial nitric oxide synthase polymorphism Glu298Asp and the blood pressure response to vitamin B6. Hypertension. 2004. PMID 26383098.
Ghasemzadeh N, et al. Endothelial dysfunction in risk stratification: a target for personalized cardiovascular prevention. PMID 30658995.
Alieva A, et al. BDNF Val66Met polymorphism and serum BDNF levels in autism spectrum disorder. Brain Res Bull. 2018. PMID 29744985.
Nakamura K, et al. Brain-derived neurotrophic factor (BDNF) and autism spectrum disorders. Curr Pharm Des. 2022. PMID 37623230.
Kroeger KM, et al. Cytokine single nucleotide polymorphisms associated with obesity. Clin Diagn Lab Immunol. 2003. PMID 18523577.
McPherson R, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316(5830):1488-91. PMID 17478681.
Helgadottir A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316(5830):1491-3. PMID 17478679.
Samani NJ, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357(5):443-53. PMID 18296591.
Cohen JC, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264-72. PMID 16169150.
Abifadel M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154-6. PMID 15654353.
Maxwell KN, et al. Novel putative PCSK9 inhibitors: small peptidomimetics that inhibit PCSK9. Arterioscler Thromb Vasc Biol. 2005. PMID 14975191.
Rétey JV, et al. A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci USA. 2001;98(24):15221-5. PMID 11073889.
Rétey JV, et al. A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther. 2007;81(5):692-8. PMID
He Y, et al. The transcriptional repressor DEC2 regulates sleep length in mammals. Science. 2009;325(5942):866-70. PMID 19798062.
Pellegrino R, et al. A novel BHLHE41 variant is associated with short sleep and resistance to sleep deprivation in humans. Sleep. 2014;37(8):1327-36. PMID 24589721.
Burke TM, et al. Effects of caffeine on the human circadian clock in vivo and in vitro. Sci Transl Med. 2015;7(305):305ra146. PMID 27775985.
